Xiaomei Ye

The PK/PD Interactions of Doxycycline against Mycoplasma gallisepticum

N. Zhang, H. Ding, Bingxu Zhang, 2016, Front. Microbiol..

A Metabolomics Approach to Investigate Kukoamine B—A Potent Natural Product With Anti-diabetic Properties

Yuanyuan Li, H. Cheung, T. Fennell, 2019, Front. Pharmacol..

Determination of the Mutant Selection Window and Evaluation of the Killing of Mycoplasma gallisepticum by Danofloxacin, Doxycycline, Tilmicosin, Tylvalosin and Valnemulin

N. Zhang, H. Ding, X. Gu, 2017, PloS one.

Relationship between Cefquinome PK/PD Parameters and Emergence of Resistance of Staphylococcus aureus in Rabbit Tissue-Cage Infection Model

Jian Sun, H. Ding, Longfei Zhang, 2016, Front. Microbiol..

Patient-reported Effects of Fedratinib, an Oral, Selective Inhibitor of Janus Kinase 2, on Myelofibrosis-related Symptoms and Health-related Quality of Life in the Randomized, Placebo-controlled, Phase III JAKARTA Trial

S. Verstovsek, R. Mesa, M. Talpaz, 2021, HemaSphere.

Health-Related Quality of Life (HRQoL) in Patients with Myelofibrosis Treated with Fedratinib, an Oral, Selective Inhibitor of Janus Kinase 2 (JAK2), in the Randomized, Placebo-Controlled, Phase III JAKARTA Study

S. Verstovsek, R. Mesa, M. Talpaz, 2019, Blood.

Health-related Quality of Life with Adjuvant Nivolumab After Radical Resection for High-risk Muscle-invasive Urothelial Carcinoma: Results from the Phase 3 CheckMate 274 Trial

J. Witjes, M. Galsky, J. Gschwend, 2021, European urology oncology.